STUDY OBJECTIVE To assess effect of intravenous recombinant tissue type plasminogen activator on size of infarct, left ventricular function, and survival in acute myocardial infarction. DESIGN Double blind, randomised, placebo controlled prospective trial of patients with acute myocardial infarction within five hours after onset of symptoms. SETTING Twenty six referral centres participating...

Intracerebral hemorrhage (ICH) is the most serious complication of intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV-r-tPA) in patients with ischemic stroke. The European Cooperative Acute Stroke Study (ECASS) defined remote parenchymal hemorrhages (rPH) as single or multiple hemorrhages that appear in brain regions without visible ischemic damage detected by crani...

Standard protocols should be established for treating eligible stroke patients with tissue plasminogen activator (TPA) (recommendation class I, level of evidence B). The Iranian standard protocol of Intravenous Thrombolysis with recombinant Tissue Plasminogen Activator (IVTTPA) is the best possible and easy to use method for performing intravenous thrombolysis in Iran. This protocol overcomes p...

background:  intravenous  recombinant  tissue plasminogen  activator  (rt-pa) is an approved  treatment for acute ischemic stroke within 4.5 h of symptoms onset. decompressive craniectomy (dc) has been  shown  as an effective  therapeutic  modality in malignant  middle cerebral  artery (mca) infarction. as rt-pa could result in hemorrhagic  complication during or after any surgery dc may be ass...

Carcinogenesis in the human colon is associated with a marked increase of urokinase type plasminogen activator and a decrease of tissue type plasminogen activator. This study was performed to determine the concentrations of urokinase type plasminogen activator and tissue type plasminogen activator in normal tissue and carcinomas along the upper part of the gastrointestinal tract. Activity and a...

Background and Purpose—Treatment of ischemic stroke by activation of endogenous plasminogen using tissue plasminogen activator is limited by bleeding side effects. In mice, treatment of experimental ischemic stroke with activated protein C improves outcomes; however, activated protein C also has bleeding side effects. In contrast, activation of endogenous protein C using thrombin mutant W215A/E...

BACKGROUND AND PURPOSE Treatment of ischemic stroke by activation of endogenous plasminogen using tissue plasminogen activator is limited by bleeding side effects. In mice, treatment of experimental ischemic stroke with activated protein C improves outcomes; however, activated protein C also has bleeding side effects. In contrast, activation of endogenous protein C using thrombin mutant W215A/E...

Abbreviations: APTT 5 activated partial thromboplastin time; ASSENT 5 Asessment of the Safety and Efficacy of a New Thrombolytic Agent; CI 5 confidence interval; FTT 5 Fibrinolytic Therapy Trialists’ Collaborative Group; GISSI 5 Gruppo Italiano per lo Studio Streptokinasi nell’Infarto Miocardico; GP 5 glycoprotein; GUSTO 5 Global Utilization of Streptokinase and TPA (alteplase) for Occluded Cor...

Recombinant tissue plasminogen activator may be effective in preventing cerebral vasospasm after subarachnoid hemorrhage by resolving subarachnoid clots. We previously demonstrated that blood placed on the adventitial surface of cerebral arteries enhances intimal platelet accumulation, positively correlating with endothelial damage and other pathologic changes in vessel walls. In this study, we...